Request SampleGlobal Glucagon-like peptide 1 (GLP-1)-based Therapies Market Growth 2022-2028
SKU ID : LPI-21207189 | Publishing Date : 05-Jul-2022 | No. of pages : 92
As the global economy mends, the 2021 growth of Glucagon-like peptide 1 (GLP-1)-based Therapies will have significant change from previous year. According to our (researcher) latest study, the global Glucagon-like peptide 1 (GLP-1)-based Therapies market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Glucagon-like peptide 1 (GLP-1)-based Therapies market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.
The United States Glucagon-like peptide 1 (GLP-1)-based Therapies market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Glucagon-like peptide 1 (GLP-1)-based Therapies market, reaching US$ million by the year 2028. As for the Europe Glucagon-like peptide 1 (GLP-1)-based Therapies landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Glucagon-like peptide 1 (GLP-1)-based Therapies players cover Novo Nordisk, AstraZeneca, Eli Lily, and GSK, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon-like peptide 1 (GLP-1)-based Therapies market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospital
Pharmacy
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
The United States Glucagon-like peptide 1 (GLP-1)-based Therapies market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Glucagon-like peptide 1 (GLP-1)-based Therapies market, reaching US$ million by the year 2028. As for the Europe Glucagon-like peptide 1 (GLP-1)-based Therapies landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Glucagon-like peptide 1 (GLP-1)-based Therapies players cover Novo Nordisk, AstraZeneca, Eli Lily, and GSK, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon-like peptide 1 (GLP-1)-based Therapies market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospital
Pharmacy
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
24/7 Research Support
Phone: +1 424 253 0807 
